Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

PubWeight™: 1.14‹?› | Rank: Top 10%

🔗 View Article (PMC 3609630)

Published in Hum Gene Ther on March 06, 2013

Authors

Dawn A Maier1, Andrea L Brennan, Shuguang Jiang, Gwendolyn K Binder-Scholl, Gary Lee, Gabriela Plesa, Zhaohui Zheng, Julio Cotte, Carmine Carpenito, Travis Wood, S Kaye Spratt, Dale Ando, Philip Gregory, Michael C Holmes, Elena E Perez, James L Riley, Richard G Carroll, Carl H June, Bruce L Levine

Author Affiliations

1: Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

Associated clinical trials:

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (Zinc-Finger) | NCT00842634

Articles citing this

Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61

Genome editing technologies: defining a path to clinic. Mol Ther (2015) 1.41

CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One (2014) 1.16

TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Res (2014) 1.16

Comparison of T7E1 and surveyor mismatch cleavage assays to detect mutations triggered by engineered nucleases. G3 (Bethesda) (2015) 1.13

Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Semin Immunol (2013) 1.11

Newer gene editing technologies toward HIV gene therapy. Viruses (2013) 1.07

Transcription activator like effector (TALE)-directed piggyBac transposition in human cells. Nucleic Acids Res (2013) 1.01

Synthetic epigenetics-towards intelligent control of epigenetic states and cell identity. Clin Epigenetics (2015) 0.99

CCR5 Gene Editing of Resting CD4(+) T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice. Mol Ther Nucleic Acids (2014) 0.96

Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. Methods (2014) 0.93

Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J Neurovirol (2015) 0.87

DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward. Virology (2014) 0.86

Rh D blood group conversion using transcription activator-like effector nucleases. Nat Commun (2015) 0.86

Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Mol Ther (2015) 0.84

Efficient Modification of the CCR5 Locus in Primary Human T Cells With megaTAL Nuclease Establishes HIV-1 Resistance. Mol Ther Nucleic Acids (2016) 0.81

Lessons to be Learned from Natural Control of HIV - Future Directions, Therapeutic, and Preventive Implications. Front Immunol (2013) 0.81

RNA interference approaches for treatment of HIV-1 infection. Genome Med (2015) 0.81

Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther (2015) 0.81

Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. Viruses (2014) 0.81

An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking. PLoS One (2014) 0.81

Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses (2013) 0.80

Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering. Mol Ther Nucleic Acids (2015) 0.80

The clinical applications of genome editing in HIV. Blood (2016) 0.79

Genetic rearrangements of variable di-residue (RVD)-containing repeat arrays in a baculoviral TALEN system. Mol Ther Methods Clin Dev (2014) 0.79

Generation of CCR5-defective CD34 cells from ZFN-driven stop codon-integrated mesenchymal stem cell clones. J Biomed Sci (2015) 0.78

Progress toward curing HIV infection with hematopoietic cell transplantation. Stem Cells Cloning (2015) 0.78

Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases. World J Hepatol (2015) 0.77

High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins. Mol Ther (2016) 0.77

A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. Cell Rep (2016) 0.77

Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy. Mol Ther (2016) 0.76

Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach. Mol Ther Nucleic Acids (2016) 0.76

Targeted Integration of a Super-Exon into the CFTR Locus Leads to Functional Correction of a Cystic Fibrosis Cell Line Model. PLoS One (2016) 0.75

Novel AIDS therapies based on gene editing. Cell Mol Life Sci (2017) 0.75

Glycosyl-phosphatidylinositol (GPI)-anchored anti-HIV scFv efficiently protect CD4 T cells from HIV-1 infection and deletion in hu-PBL mice. J Virol (2016) 0.75

Articles cited by this

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77

Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 19.15

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75

Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A (1996) 12.25

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68

Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 9.76

NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 7.78

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55

An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol (2011) 6.44

Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood (2005) 6.16

Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A (2002) 6.05

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med (2004) 5.49

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99

Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med (1996) 4.57

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32

Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65

T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today (1995) 3.60

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med (1997) 3.40

Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J Biol Chem (2001) 3.38

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother (2009) 3.11

Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med (1998) 2.99

Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol (1997) 2.98

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood (2003) 2.83

Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 2.81

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64

Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol (2000) 2.63

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol (2004) 2.58

A detailed study of the substrate specificity of a chimeric restriction enzyme. Nucleic Acids Res (1999) 2.54

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood (2005) 2.39

HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet (1998) 2.32

Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc Natl Acad Sci U S A (2003) 2.24

Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science (1996) 2.11

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93

Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther (2005) 1.89

Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS (1997) 1.83

Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet (1999) 1.65

Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood (1997) 1.58

Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood (2003) 1.54

Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med (2004) 1.54

Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J Clin Invest (1997) 1.46

Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 1.44

CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol (1995) 1.40

Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res (2009) 1.38

CCR2 chemokine receptor and AIDS progression. Nat Med (1997) 1.34

Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther (2002) 1.27

Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp Hematol (2007) 1.25

Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother (2000) 1.22

Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Exp Hematol (2004) 1.17

Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother (1998) 1.16

Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy (2009) 1.13

Zinc-finger nucleases for somatic gene therapy: the next frontier. Hum Gene Ther (2011) 1.11

Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS (2011) 1.09

Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors. Cancer Res (2003) 1.09

Chemokines as natural HIV antagonists. Curr Mol Med (2002) 1.05

Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol (2005) 1.01

GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy (2004) 1.01

Efficient adenovirus-mediated gene transfer into primary T cells and thymocytes in a new coxsackie/adenovirus receptor transgenic model. BMC Immunol (2002) 1.00

Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy. AIDS (1999) 0.96

Different qualitative and quantitative regulation of V beta TCR transcripts during early acute allograft rejection and tolerance induction. J Immunol (2002) 0.96

Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J Immunol (2000) 0.96

Gene therapy: a bold direction for HIV-1 treatment. AIDS Res Hum Retroviruses (1993) 0.95

Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant (2004) 0.94

Direct recognition of foreign MHC determinants by naive T cells mobilizes specific Vbeta families without skewing of the complementarity-determining region 3 length distribution. J Immunol (2001) 0.91

Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts. J Immunol (2000) 0.91

Limits of the human-PBL-SCID mice model: severe restriction of the V beta T-cell repertoire of engrafted human T cells. Blood (1997) 0.90

In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine (2003) 0.90

Progression of human immunodeficiency virus disease is associated with increasing disruptions within the CD4+ T cell receptor repertoire. J Infect Dis (1998) 0.88

Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Hum Gene Ther (2006) 0.88

Longitudinal changes in CD4+ T cell antigen receptor diversity and naive/memory cell phenotype during 9 to 26 months of antiretroviral therapy of HIV-infected patients. AIDS Res Hum Retroviruses (2000) 0.87

High-efficiency gene transfer to primary T lymphocytes by recombinant adenovirus vectors. J Immunol Methods (2002) 0.85

Evaluation of TCR Vbeta subfamily T cell expansion in NOD/SCID mice transplanted with human cord blood hematopoietic stem cells. Hematology (2007) 0.84

Duplex polymerase chain reaction quantification of human cells in a murine background. Stem Cells (2005) 0.81

Efficient gene transfer into hematopoietic cells by a retargeting adenoviral vector system with a chimeric fiber of adenovirus serotype 5 and 11p. Exp Hematol (2006) 0.81

EBV-induced human B cell lymphomas in hu-PBL-SCID mice. AIDS Res Hum Retroviruses (1992) 0.81

Efficient gene transfer into normal human B lymphocytes with the chimeric adenoviral vector Ad5/F35. J Immunol Methods (2005) 0.78

Blocking HIV's attack. Sci Am (2012) 0.78

Articles by these authors

A TALE nuclease architecture for efficient genome editing. Nat Biotechnol (2010) 26.47

Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 19.15

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99

Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 18.88

An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol (2007) 17.80

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 9.23

Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell (2010) 8.79

Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64

A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91

A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol (2010) 6.77

The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 6.65

Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A (2008) 6.59

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55

An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol (2011) 6.44

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18

Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods (2010) 6.00

Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci U S A (2007) 5.93

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10

Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature (2011) 4.92

In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58

Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65

Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat Methods (2010) 3.59

Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43

FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci U S A (2007) 3.32

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29

Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21

DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology (2003) 3.20

Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06

Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol (2012) 3.01

Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther (2007) 2.99

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91

L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90

CARs on track in the clinic. Mol Ther (2011) 2.86

Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood (2003) 2.83

Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 2.81

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77

Chromosomal translocations induced at specified loci in human stem cells. Proc Natl Acad Sci U S A (2009) 2.73

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69

Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64

Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood (2004) 2.63